The t(1;19)(q23;p13) is the most common recurring chromosomal translocation in childhood acute lymphoblastic leukemia (ALL) and has been associated with adverse prognosis. It involves the rearrangement of t w o genes, PBXl and E2A. resulting in the production of transforming chimeric DNAbinding proteins. In all previous reports in which the presence of a chimeric transcript was described, the fusion point between the coding sequences of E2A and PBXl was found t o be constant at the RNA level. We have used RNA-based polymerase chain reaction (PCR) for the detection of E2AI PBXl messenger RNAs (mRNAs) in children with ALL at the time of diagnosis. Of 21 patients exhibiting this rearrangement, 3 (14%) expressed a variant E2A/PBXl transcript in addition t o the expected one. The relative amounts of the HE CHROMOSOMAL translocation t(1;19)(q23;p13)
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T is the most prevalent nonrandom translocation in pediatric acute lymphoblastic leukemia (ALL), occuring predominantly, but not exclusively, in pre-B-ALL.' Clinically, the presence of the t(1;19) has been associated with a poor prognosis? Rivera et aP have recently shown that the prognosis improved when the patients were treated with an intensified chemotherapeutic protocol. These findings emphasize the clinical importance of detecting patients who carry this genetic rearrangement.
In most t(l;l9)-positive cases of ALL, this translocation results in the fusion between two genes that encode DNA binding proteins. PBXl gene sequences from chromosome 1 are inserted into the E2A gene on chromosome 19.4~~ The novel chimeric messenger RNA (mRNA) is translated into several putative transcription factors consisting of the E2A transactivating domain and the PBXl DNA-binding domain. These chimeric E2A/PBX1 proteins have been shown to induce malignant transformation in experimental models? Hunger et a17 reported that the junction between E2A and PBXl coding sequences occurs at precisely the same site in all patients displaying the E2A/PBX1 chimeric RNA. The constant breakpoints at the RNA level rendered this clinically important gene rearrangement amenable to routine diagnosis by polymerase chain reaction (PCR). Using this approach, a small number of t(l;l9)-positive patients were identified who had no evidence for expression of the chimerica RNA6,7 (our own unpublished observations). In a recent study, the association of E2A rearrangements and expression of E2A/PBX1 fusion proteins was shown to coincide with the expression of cytoplasmic Ig p heavy chains (cIg).8 For the t(l;l9)-positive and E2A/PBX1-negative cases, a different molecular rearrangement was suggested.
We have applied RNA-based PCR analysis to the detection of the E2A/PBX1 fusion mRNAs in bone marrow and peripheral blood samples of pediatric patients with ALL? In this report, we describe the occurence of a novel variant two chimeric mRNAs varied between the patients, but remained constant in the same patient during different stages of the disease. Sequence analysis showed an identical insertion of 27 bp at the E2A/PBX1 junction of the variant RNA species, the translation of which would result in the replacement of Val478 by 10 amino acids. The inserted sequence has not been detected in any other human transcript besides the variant EZA/PBXl RNA species and probably represents a splicing variant of the chimeric RNA. We conclude that a subset of pediatric patients with ALL that carry the E2A/ PBXl rearrangement express t w o types of the chimeric mRNA. The biologic significance of this additional E2A/ PBXl transcript is discussed. 0 1992 by The American Society of Hematology.
transcript in a subset of patients expressing the rearranged E2A/PBX1 fusion gene. RNA extraction and reversed PCR were performed as described previo~sly.~ To verify the specificity of amplified products and to increase the sensitivity, 3 pL of a 1:1,000 dilution of the first round product was subjected to a second round of nested PCR for 35 cycles. The quality of the cDNA and the validity of the negative results were assessed by parallel amplification of the ubiquitously expressed E2A mRNA. Strict precautions against contamination were ~ndertaken.'~ Negative and positive controls were included throughout RNA extraction, reverse transcription, and PCR. PCR of every positive case was repeated with new cDNA and, if available, with a different RNA preparation from another cell specimen of the same patient. PCR products were separated in 3% agarose gels and visualized by staining with ethidium bromide.
MATERIALS AND METHODS

Patients
Northern and Southern blot hybridizations to radiolabeled oligonucleotides were performed essentially as described previously.ls Direct sequencing of PCR products was performed essentially as reported previously.16 Confirmation of the sequence identity of PCR products was performed by analysis of single strand conformation polymorphisms (SSCP)" as described by Orita et al.lR
Hyhridizurion.
Sequencing and SSCP ana/ysis.
RESULTS
Identification of E24IPBXl type la RNA. All 21 patients in whom E2A/PBXl fusion mRNA was detected by PCR exhibited amplification products of the expected size (Fig 1,  type I; Fig 2) . The correspondence of these PCR products with the published E2A/PBXl sequence4 was verified by direct sequencing in two cases and by SSCP analysis in the remaining patients (data not shown). Unexpectedly, in three patients, an additional, slightly larger transcript was amplified by PCR (Fig 1, type Ia). Coamplification of two different E2A/PBXl fragments in the same PCR reaction provides a basis for quantitative estimation of the relative amounts of both mRNA species in the cells ana1y~ed.I~ The proportions between the common and the variant E2A/ PBXl transcripts amplified showed interindividual differences. Type la transcript was the predominant PCR product in patient B, whereas type I was much more abundant in patient A (Fig 1A) . In the third patient, both transcripts were present in equal amounts (data not shown). However, within the same patient, the ratio between the quantities of the two transcripts was constant in repeated experiments with different cDNA preparations. Moreover, in one patient, PCR analyses of bone marrow specimens from the time of relapse (Fig lA, lane A2) showed the same relative amounts of the two alternative transcripts as observed in a specimen collected at diagnosis (Fig lA, lane Al) .
Sequencing of the type Ia fragment showed identical insertions of 27 bp at the E2A/PBXl junction in all three patients (Fig 1B) . Amplified E2A/PBXl products from all 21 patients investigated were hybridized to probes specific for the variant insert of the type Ia transcript. Positive signals were obtained only in specimens from the three patients, in whom an additional band was already seen after electrophoresis of the PCR products in ethidium bromidestained gels (data not shown). As shown in Fig 2, no transcripts containing sequences homologous to the 27-bp insert were identified in ALLcell lines containing either the E2A/PBXl (cell lines 697, lanes 3, 4, and 6) or the BCR/ABL rearrangement (SUP-Bl5, lanes 1.2, and 5) or in neuroblastoma cell lines expressing a normal PBXl transcript (STA-NB-2, LA-N-1, and VI 856, lanes 8.9, and 10, respectively), which is slightly smaller than the rearranged one (compare lanes 11 and 12) .
Comparison of the insert in the E2A/PBX1 transcript type Ia to sequence data bases showed no significant homology to any known sequence, including the E2A coding sequence? In addition, a 146-bp fragment amplified from a normal PBXl cDNA and located upstream of the rearrangement point in E2A/PBX1 chimeric RNA does not include the type la-specific 27-bp segment (data not shown). The insert was used as an oligonucleotide probe for hybridization to Southern blots of genomic DNA from cells expressing or lacking the variant E2A/PBXl mRNA. In all instances, the probe hybridized to at least 8 different fragments generated by digestion with various restriction enzymes. At least some of these fragments originated from chromosomes other than 1 or 19, as indicated by analysis of mouse-human hybrid cell lines containing small numbers of defined human chromosomes. Northern blot hybridization of total cellular RNA to a variant-specific sense oligonucleotide showed that sequences homologous to the 27-bp insert are present in some expressed genes in inverted orientation (data not shown). Similarly, a number of different restriction fragments derived from PBX1-related sequences hybridized to a PBX1-specific oligonucleotide that flanks the rearrangement site in E2A/PBXl transcripts.I9 Amplification of genomic DNA with either E2A or PBXl upstream and downstream primers flanking the rearrangement site did not yield any PCR products hybridizing to the variant type la insert. Additional DNA-and RNA-based PCR Origin of rhe insert in E2A /PBXl rype la mRNA. ( l a m 1, 3, 5,6,8, 9, 10, and 12) RNA war hybridized either to an oligonucleotide homologour to the type la i n w e (lanes 1 through 10) or to an 88-bp PBX1-specific probe generated by PCR amplification (loner 11 and 12). Hybridization to a human @actin probe is shown as a control. 
DISCUSSION
In this report, we show that a subset of pediatric ALL patients carrying the E2A/PBXl rearrangement express a hitherto unknown variant E2A/PBXl fusion mRNA. In our series, the novel RNA species was detected in 3 of 21 patients investigated. This variant chimeric mRNA, which we termed "type Ia" transcript, contained an insert of 27 bases at the E2A/PBXl junction. In a previous study, PCR analysis in a larger series of ALL patients displaying PCRdetectable chimeric E2A/PBXl RNA showed only one type of E2A/PBXl transcript.' Therefore, the detection of an additional E2A/PBXl mRNA species was surprising. In the study conducted by Hunger et a17 the PCR products were separated in 1.3% agarose gels. Therefore, the presence of the type Ia transcript in some of these patients cannot be completely excluded because an additional amplification product differing in size by 27 bp may have escaped the detection. Moreover, the oligonucleotide probe used in the previous study for the identification of the specific E2A/PBX1 sequences would have hybridized only to the PCR products resulting from transcript type I, but not type la. It is possible, therefore, that reexamination of these cases would result in the identification of patients P B X l B-actin expressing the type Ia mRNA species. The ALL patients in whom both types of the chimeric message were detected expressed the two E2A/PBX1 species at different proportions (Fig 1A) . In the same individual patient, however, the ratio remained constant in different samples analyzed during the course of the disease. We suggest, therefore, that type I and type Ia E2A/PBX1 fusion mRNAs are splicing variants of the same rearrangement that are expressed in the same malignant clone. When regarding ALL as a clonal disease, the coexistence of two leukemic clones, in each of which a different type of E2A/PBXl rearrangement is expressed, would be a less likely interpretation of our results.
Computer-aided theoretical secondary structure analysis of the type Ia chimeric protein by the method of Chou and FasmanM suggested that the insertion does not significantly alter the protein structure. Thus, the functional activity of the chimeric protein is probably not impaired. CCRl'(14) ALLt (7) The letters A, 6, and C (see Fig 1A) designate patients displaying both transcripts (I + la). Data from the 18 patients expressing onlytype I E2A/PBX1 Abbreviation: CCRl complete clinical remission 1. *Current status 13 to 78 months after diagnosis. Immunologic subtypes were classified as follows*4: CALL: CD19+, TdT+, HLADR+, CD10+, clg-; mRNA are presented as a summary. The figures in parentheses indicate the number of patients.
ALLt: CD19+, TdT+, HLADR+, CD10+, clg not determined; pre-5-ALL: CD19+, TdT+, HLADR+, CD10+, clg+. the t(9;22)(q34;qll), a translocation characteristic for chronic myloid leukemia and a subset of ALL, ABL exon I1 alternatively splices to one of two adjacent BCR exons?1 Similarly, in patients with acute promyelocytic leukemia, splicing variants of the PML/RAR fusion gene associated with the translocation t(15;17)(q22;qll-21)22 have been recently described. 23 Kamps et a16 reported the detection of five related species of E2A/PBX1 proteins in pre-B-ALL by immunoblot analysis. At least two of the protein species resulted from chimeric transcripts differing in their 3' ends biologic properties. Comparison of the clinical and immunologic features showed no striking differences between the three patients displaying the variant transcript and the 18 patients expressing only type I E2A/PBX1 RNA (Table 1) . It should be noted, however, that the white blood cell (WBC) counts at diagnosis were rather high (50.3 to 148.5 x lo9 cells/mL) in the three patients expressing both mRNA species as compared with most (13 of 18) of the patients with type I transcript only. Further studies are required to elucidate the significance of these observations. as a result of alternative splicing. Upon introduction into NIH3T3 cells, the corresponding cDNAs displayed different Potentials in malignant transformation. we do not know presently whether the chimeric proteins resulting from type I and type Ia E2A/PBX1 mRNA differ in their
